Shares of Immunovant, Inc. (IMVT) plummeted 8.01% in pre-market trading on Monday following the release of its second-quarter financial results and clinical trial updates. The biopharmaceutical company, focused on developing innovative treatments for autoimmune diseases, reported a wider-than-expected loss and announced delays in reporting results for key clinical trials.

For the fiscal second quarter ended September 30, 2025, Immunovant reported a net loss of $126.5 million, or $0.73 per share, compared to a loss of $109.1 million, or $0.74 per share, in the same period last year. The result missed analysts' expectations, with the consensus estimate calling for a loss of $0.72 per share. The company's operating expenses increased to $131.76 million, primarily due to higher research and development costs associated with its clinical trials.

While Immunovant highlighted positive developments in its clinical programs, including promising results from its study of uncontrolled Graves' disease patients, investors seemed to focus on the delay in reporting results for the company's thyroid eye disease (TED) studies. The company now anticipates sharing topline results from both TED studies concurrently in the first half of 2026, citing "evolving competitive dynamics." This delay appears to have contributed significantly to the negative market reaction. Despite the setbacks, Immunovant reported a strong cash position of $521.9 million as of September 30, 2025, which the company believes will provide runway through the expected Graves' disease readout in 2027.